Jiangsu Synthgene Biotechnology

CRO focused on development of invitro diagnostic reagents

placeNanjing, Jiangsu, China calendar_todayFounded 2018 groups22 employees language syngenebio.com

Innovation

53 patent families (16 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 200 times.

YearFilings
201913
20207
20211
20223
202319
202410
20258
20263

Investor mix

6 investors on record.

Investor typeCountShare
Venture capital350%
Private equity233%
Other / undisclosed117%
Coming soon